Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Ferran Fece de la Cruz

Group Leader

Rigshospitalet

Denmark

Research Interests

Articles (6)

Year:

2026

Year:

2026

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Collaborators (3)

Jessica Lin

Massachusetts General Hospital

UNITED STATES

View details

Ioannis Sanidas

Principal Investigator

Massachusetts General Hospital

UNITED STATES

View details

Michael Rosenthal

Brigham and Women's Hospital

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ferran Fece de la Cruz

Research Interests

Articles (6)

Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition

Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators

Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS<SUP>G12C</SUP> inhibitors

Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers

Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma

Collaborators (3)

Jessica Lin

Ioannis Sanidas

Michael Rosenthal

Make your next move.